FOXO4-DRI
FOXO4-DRI is an experimental senolytic peptide approach studied in cells and mice, not a clinically established anti-aging therapy.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
FOXO4-DRI denotes the D-retro-inverso cell-penetrating research peptide defined in the cited primary study; that identity does not automatically apply to commercial products.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The study examined cell models and fitness, fur and kidney function in aged or injured mice.
- Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and agingAnimal study2017
Baar MP et al.
Accessed:
Research gaps
- ·The findings establish neither lifespan extension nor clinical benefit. Human studies, independent clinical replication and long-term toxicology are absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
In preclinical models the approach disrupts the FOXO4–p53 interaction in senescent cells and promotes their apoptosis.
- Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and agingAnimal study2017
Baar MP et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. Effects of disrupting the FOXO4–p53 axis, off-target effects and long-term human toxicity are unknown.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·The findings establish neither lifespan extension nor clinical benefit. Human studies, independent clinical replication and long-term toxicology are absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and agingAnimal study2017
Baar MP et al.
Accessed:
Sources
Sources checked: · Version 3
- Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and agingAnimal study2017
Baar MP et al.
Accessed: